Fox Chase Cancer Center Receives CEO Cancer Gold Standard™ accreditation
CARY, NC (September 1, 2009) – Fox Chase Cancer Center has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to the health of their employees and family members by certifying their efforts to meet an exceptionally high standard of cancer prevention, screening and care guidelines.
William C. Weldon, chairman and chief executive officer of Johnson and Johnson chairs the CEO Roundtable on Cancer, the nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard™, in collaboration with the National Cancer Institute, many of its designated cancer centers, the American Cancer Society, CDC and leading health professionals.
“As Dr. Michael Seiden, president and CEO of Fox Chase Cancer Center, and his leadership team help lead the fight against cancer, our Gold Standard certification acknowledges that their efforts begin with a commitment to the health of their employees and their family members,” said Weldon.
The CEO Cancer Gold Standard™, calls for companies to evaluate their benefits and culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use and encouraging physical activity, healthy diet and nutrition; detect cancer at its earliest stages; and provide access to quality care, including the availability of clinical trials.
The most recent President's Cancer Panel report, “Maximizing our Nation’s Investment in Cancer: Three Crucial Actions for America’s Health”, identified the CEO Cancer Gold Standard as an initiative that emphasizes cancer screening, tobacco control, cancer education, lifestyle modification, and access to cancer treatment when needed.
Fox Chase becomes the seventh NCI-designated cancer center to achieve Gold Standard accreditation, joining with the National Cancer Institute, who also achieved Gold Standard accreditation late last year. Other organizations championing this workplace-based effort to eliminate cancer as a public health threat include: American Cancer Society, American Legacy Foundation, AstraZeneca, C-Change, CIGNA, Dana-Farber Cancer Institute, Duke Medicine, Edelman, Enzon Pharmaceuticals, GHI, an EmblemHealth company, GlaxoSmithKline, Hogan & Hartson, Jenner & Block, Johnson & Johnson, The Lance Armstrong Foundation, MD Anderson Cancer Center, Millennium: The Takeda Oncology Company, Minot State University, H. Lee Moffitt Cancer Center and Research Institute, The National Cancer Institute (NCI), Novartis, The Oncology Nursing Society, OSI Pharmaceuticals, Pfizer, PhRMA, PPD, Quintiles Transnational, sanofi-aventis, SAS Institute, The University of North Dakota, US Oncology, Valeant Pharmaceuticals, Vanderbilt-Ingram Cancer Center, Virtua Health and The Wistar Institute.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Diana Quattrone at 215-728-7784.